Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

@article{Siegel2008PhaseIT,
  title={Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.},
  author={Abby B. Siegel and Emil Cohen and Allyson J. Ocean and Deborah Lehrer and Alec S. Goldenberg and Jennifer J. Knox and Helen H. W. Chen and Sean Clark-Garvey and Alan Weinberg and John Mandeli and Paul J. Christos and Madhu Mazumdar and Elizabeta Popa and Robert S Brown and Shahin Rafii and Jonathan D Schwartz},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 18},
  pages={2992-8}
}
PURPOSE To determine the clinical and biologic effects of bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, in unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS Adults with organ-confined HCC, Eastern Cooperative Oncology Group performance status of 0 to 2, and compensated liver disease were eligible. Patients received bevacizumab 5 mg/kg (n = 12) or 10 mg/kg (n = 34) every 2 weeks until disease progression or treatment-limiting toxicity. The… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 152 extracted citations

Similar Papers

Loading similar papers…